Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew N Phillips

Showing results (111-120 of 287) with videos related to

Pageof 29
Sort By:
The Journal of Antimicrobial Chemotherapy|November 19, 2016
HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UKKate El Bouzidi, Ellen White, Jean L Mbisa, et al.
The Lancet. Global Health|June 29, 2026
Sustaining progress in HIV care in Africa with a transition to enabled self-care: a modelling studyAndrew N Phillips, Kenly Sikwese, Valentina Cambiano, et al.
The Lancet. HIV|May 9, 2017
Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort studyJemma O'Connor, Colette Smith, Fiona C Lampe, et al.
The Journal of Infectious Diseases|October 2, 2002
Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppressionAndrew N Phillips, Schlomo Staszewski, Fiona Lampe, et al.
AIDS (London, England)|March 20, 2010
Long-term trends in adherence to antiretroviral therapy from start of HAARTValentina Cambiano, Fiona C Lampe, Alison J Rodger, et al.
AIDS (London, England)|April 18, 2003
The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapyColette J Smith, Caroline A Sabin, Fiona C Lampe, et al.
The Journal of Infectious Diseases|May 2, 2016
Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV InfectionÁlvaro H Borges, Jemma L O'Connor, Andrew N Phillips, et al.
JMIR Research Protocols|June 17, 2016
Attitudes to and Understanding of Risk of Acquisition of HIV Over Time: Design and Methods for an Internet-based Prospective Cohort Study Among UK Men Who Have Sex With Men (the AURAH2 Study)Janey Sewell, Andrew Speakman, Andrew N Phillips, et al.
AIDS (London, England)|November 7, 2015
Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?Inma Jarrin, Nikos Pantazis, Judith Dalmau, et al.
AIDS (London, England)|August 28, 2007
Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-scoreAmanda Mocroft, Bruno Ledergerber, Kai Zilmer, et al.
Pageof 29

Showing results (111-120 of 287) with videos related to

Sort By:
Pageof 29
The Journal of Antimicrobial Chemotherapy|November 19, 2016
HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UKKate El Bouzidi, Ellen White, Jean L Mbisa, et al.
The Lancet. Global Health|June 29, 2026
Sustaining progress in HIV care in Africa with a transition to enabled self-care: a modelling studyAndrew N Phillips, Kenly Sikwese, Valentina Cambiano, et al.
The Lancet. HIV|May 9, 2017
Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort studyJemma O'Connor, Colette Smith, Fiona C Lampe, et al.
The Journal of Infectious Diseases|October 2, 2002
Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppressionAndrew N Phillips, Schlomo Staszewski, Fiona Lampe, et al.
AIDS (London, England)|March 20, 2010
Long-term trends in adherence to antiretroviral therapy from start of HAARTValentina Cambiano, Fiona C Lampe, Alison J Rodger, et al.
AIDS (London, England)|April 18, 2003
The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapyColette J Smith, Caroline A Sabin, Fiona C Lampe, et al.
The Journal of Infectious Diseases|May 2, 2016
Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV InfectionÁlvaro H Borges, Jemma L O'Connor, Andrew N Phillips, et al.
JMIR Research Protocols|June 17, 2016
Attitudes to and Understanding of Risk of Acquisition of HIV Over Time: Design and Methods for an Internet-based Prospective Cohort Study Among UK Men Who Have Sex With Men (the AURAH2 Study)Janey Sewell, Andrew Speakman, Andrew N Phillips, et al.
AIDS (London, England)|November 7, 2015
Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4+ T-cell recovery once HIV-1 suppression is achieved?Inma Jarrin, Nikos Pantazis, Judith Dalmau, et al.
AIDS (London, England)|August 28, 2007
Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-scoreAmanda Mocroft, Bruno Ledergerber, Kai Zilmer, et al.
Pageof 29